Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
Britain's Magnificent 7: Do Rolls-Royce, AstraZeneca and Unilever make the cut?
09:21am, Wednesday, 24'th Apr 2024
The Magnificent 7 will be hogging US financial news headlines over the coming weeks. Not to be confused with the Yul Byrnner-starring 60s Western classic, the term refers to the seven premier Big Tech
ANGLE shares jump 30% on AstraZeneca tie-up
07:37am, Wednesday, 24'th Apr 2024
ANGLE PLC (AIM:AGL, OTCQX:ANPCY) shares jumped 30% following the announcement of a strategic partnership with AstraZeneca PLC (LSE:AZN) that aims to advance cancer drug development by enhancing the
AstraZeneca: What The Market's Missing
04:30am, Wednesday, 24'th Apr 2024
AstraZeneca: What The Market's Missing
ANGLE inks AstraZeneca deal to develop ground-breaking cancer assay
02:34am, Wednesday, 24'th Apr 2024
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the developer of liquid biopsy technologies, has partnered with AstraZeneca PLC (LSE:AZN) to enhance cancer drug development by 'leveraging' the former's DNA damage r
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
03:00pm, Tuesday, 23'rd Apr 2024
Big money tends to flow from one sector to the other. During the pandemic, sectors like pharmaceutical and e-commerce were hot.
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
11:01am, Tuesday, 23'rd Apr 2024
Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.
3 Blue-Chip Stocks to Buy as High Inflation Persists
06:10am, Friday, 19'th Apr 2024
Inflation in the United States has been stubborn and a matter of concern for policymakers. For March, the consumer price increase rose by 3.5% on a year-on-year basis, which was more than expected.
Astrazeneca (AZN) Could Be a Great Choice
12:46pm, Thursday, 18'th Apr 2024
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes?
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.
07:09pm, Tuesday, 16'th Apr 2024
A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.
AstraZeneca upgrade (of sorts) by leading investment bank
06:48am, Tuesday, 16'th Apr 2024
AstraZeneca PLC (LSE:AZN) has been upgraded by a leading investment bank following guidance on the company's dividend policy, and a more positive earnings outlook. Deutsche Bank has moved to 'hold' fr
3 Pharma Stocks That Are Money-Printing Machines in 2024
05:51pm, Monday, 15'th Apr 2024
The future of the U.S. economy appears promising, with robust growth and strong corporate performance. This economic strength has propelled the stock market to record highs, signaling confidence in th
AstraZeneca: A case of steady-as-she-goes, says broker
09:03am, Monday, 15'th Apr 2024
AstraZeneca PLC (LSE:AZN) is poised to maintain its full-year financial guidance without adjustments when it announces its first-quarter results later this month (April 25), according to insights fro
U.K. Top 40 Quality Dividend Stocks: Q2 2024
01:30pm, Friday, 12'th Apr 2024
The list ranks stocks based on their market cap and dividend yield alone. What I am looking for is quality dividend stocks with long track records of progressive dividend growth, and while dividend yi
AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
11:36am, Friday, 12'th Apr 2024
The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.
Was AstraZeneca boss Soriot's pay rise controversial? Not particularly
08:54am, Friday, 12'th Apr 2024
It was framed as a pitched battle between two opposing camps in AstraZeneca PLC (LSE:AZN)'s shareholder base. On one side, chief executive Pascal Soriot's 11% annual remuneration hike was egregious, e
